What short‑acting as‑needed (PRN) medication can be used for a psychiatric patient who is unable to sit still?

PRN Medication for Psychiatric Patients Unable to Sit Still

For a psychiatric patient unable to sit still (likely akathisia or acute agitation), use lorazepam 1-2 mg IM/IV or haloperidol 5 mg IM as first-line PRN monotherapy, with benzodiazepines preferred if the restlessness is akathisia from antipsychotic use. 1

Understanding the Clinical Context

The inability to sit still in a psychiatric patient requires immediate differentiation between two distinct scenarios:

If This is Akathisia (Antipsychotic-Induced Restlessness)

Akathisia is a medication side effect, not agitation requiring more antipsychotics. The treatment approach differs fundamentally:

• Lower the antipsychotic dose currently being administered
• Switch to a different antipsychotic with lower akathisia risk
• Add a benzodiazepine (lorazepam 1-2 mg) 2
• Add a beta-blocker as an alternative 2

The APA guidelines specifically recommend these options for akathisia management, emphasizing that adding more antipsychotics would worsen the problem 2.

If This is Acute Agitation/Psychomotor Agitation

For undifferentiated acute agitation where the patient cannot sit still due to psychiatric symptoms rather than medication side effects:

First-Line PRN Options

Benzodiazepine Monotherapy:

• Lorazepam 2-4 mg IM/IV is as effective as haloperidol for acute agitation 1
• Multiple Class II studies demonstrate benzodiazepines are at least as effective as conventional antipsychotics 1
• Lorazepam has a relatively benign adverse effect profile compared to antipsychotics 3
• Can be given IM, IV, PO, or sublingual 4

Conventional Antipsychotic Monotherapy:

• Haloperidol 5 mg IM has the strongest evidence base among conventional antipsychotics 1
• 20 double-blind studies since 1973 support haloperidol use for agitation 1
• Caution: Anticipated extrapyramidal symptoms, which could worsen the inability to sit still 5

Alternative and Combination Approaches

Atypical Antipsychotics (if available):

• Ziprasidone 20 mg IM is effective with notably absent movement disorders, including extrapyramidal symptoms 1
• Olanzapine 5-10 mg IM is effective but has high sedative potential 6
• Aripiprazole 5 mg IM has low sedative potential 6

Combination Therapy:

• Haloperidol 5 mg + Lorazepam 2 mg IM may produce more rapid sedation than monotherapy 1
• This is Level C evidence (weaker than monotherapy recommendations) 1
• Standard protocol at many institutions 3

Critical Decision Points

Choose Benzodiazepines If:

• The patient is already on antipsychotics (akathisia risk)
• You want to avoid extrapyramidal symptoms that could worsen restlessness
• The patient has substance withdrawal contributing to agitation 4
• Rapid sedation without movement disorders is the priority

Choose Antipsychotics If:

• The patient has known psychotic disorder with severe psychomotor agitation 5
• Delusions or hallucinations are driving the agitation 5
• The patient is not currently on antipsychotics (lower akathisia risk)

Practical Dosing Guidance

For Immediate Use:

• Lorazepam: Start 1-2 mg IM/IV, can repeat q1h PRN (use lower doses 0.25-0.5 mg if elderly/frail or if combining with antipsychotic) 4
• Haloperidol: 5 mg IM, can repeat as needed 1
• Ziprasidone: 20 mg IM (if available), superior to 10 mg dose 1

For Cooperative Patients:

• Oral combination of lorazepam 2 mg + risperidone (atypical antipsychotic) is effective 1
• Oral formulations show similar improvement with similar time to sedation 1

Safety Considerations

Common Pitfalls to Avoid:

1. Do not assume restlessness = need for more antipsychotics. This could be akathisia requiring dose reduction, not escalation 2

2. Avoid anticholinergics (benztropine, trihexyphenidyl) in elderly patients with typical antipsychotics, as these increase anticholinergic burden 5

3. Use lower benzodiazepine doses (0.25-0.5 mg) when combining with antipsychotics to reduce fall risk and respiratory depression 4

4. Monitor for paradoxical agitation with benzodiazepines (occurs in ~10% of patients) 5

5. Assess for medical causes of agitation (anticholinergic toxicity, sympathomimetic ingestion) before administering medications that could worsen the condition 1

Adverse Events:

• Extrapyramidal symptoms occur with antipsychotics but are rare with atypicals like ziprasidone 1
• Benzodiazepines carry fall risk, especially in elderly/frail patients 4
• Combination therapy increases sedation and fall risk 4

Monitoring After Administration

• Reassess within 5-15 minutes for IM medications
• If inadequate response: Can repeat dose or add second agent
• If excessive sedation: Monitor respiratory status, especially with combinations
• If dystonia develops: Treat immediately with anticholinergic medication 2

The 2006 emergency department guidelines provide Level B recommendations supporting both benzodiazepines and conventional antipsychotics as effective monotherapy, with the choice depending on whether the restlessness is medication-induced (favoring benzodiazepines) or symptom-driven (allowing either approach) 1.